Azvudine beats paxlovid in reducing COVID-19 deaths

In hospitalized COVID-19 patients, azvudine shows lower all-cause mortality and fewer adverse events than Paxlovid, with added antitumor effects observed.

Exposure to styrene and ethylbenzene elevates diabetes risk

Type 2 diabetes mellitus (T2DM) is a critical public health issue, with its prevalence expected to rise sharply worldwide.

September 18, 2024

Tracking the FDA advisory panel on the first CRISPR-based treatment for sickle cell disease

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made

October 31, 2023

Sorrento Therapeutics Inc Files Patent for Stable Oral Liquid Pharmaceutical Composition of Celecoxib

Share this article According to GlobalData’s company profile on Sorrento Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents. Sorrento Therapeutics‘s grant

March 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.